NASD · Healthcare · Biotechnology · Switzerland
CRISPR Therapeutics AG is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
CRISPR Therapeutics AG is a biopharmaceutical company developing gene-editing medicines using CRISPR/Cas9 technology for serious human diseases. The company's portfolio spans four franchises: hemoglobinopathies, in vivo liver editing, CAR T cell therapies, and regenerative medicine. CASGEVY, its lead approved therapy developed with Vertex Pharmaceuticals, treats severe sickle cell disease and beta thalassemia.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the CRISPR Therapeutics AG stock.
Overvalued: intrinsic value $16.98 per share, market price $50.04, margin of safety -194.6% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $16.98; the price of $50.04 is 195% above that value.
Leak Score: 25/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
69 more in this industry show a wider margin of safety.
CRSP is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $16.98; the price of $50.04 is 195% above that value.
$16.98 per share (as of the 2026-10-19 close), against a market price of $50.04. That is a margin of safety of -194.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
25 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.